Finasteride vs Avodart (Dutasteride): Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Finasteride and dutasteride both belong to the 5-alpha reductase inhibitor (5-ARI) class, and both reduce dihydrotestosterone (DHT), the androgen responsible for miniaturizing hair follicles in androgenetic alopecia (AGA). Finasteride selectively blocks the type II isoenzyme of 5-alpha reductase, while dutasteride inhibits both type I and type II isoenzymes [1].

That dual inhibition gives dutasteride a pharmacologic edge on paper. Serum DHT drops by roughly 70% with finasteride 1 mg daily and by over 90% with dutasteride 0.5 mg daily, according to data reviewed by the American Academy of Dermatology and subsequent comparative studies [2]. The clinical question is whether that extra DHT suppression translates into meaningfully better hair outcomes, and whether the cost and access differences justify one drug over the other.

Prescribers and patients end up comparing them because dutasteride's off-label use for AGA has grown steadily, particularly in South Korea, Japan, and parts of Europe where regulatory approval for hair loss exists. In the United States, the comparison demands closer attention to formulary status, insurance billing codes, and pharmacy stocking practices, because those factors can make a $10-per-month drug effectively unavailable to a patient whose plan only reimburses the $300-per-month alternative for benign prostatic hyperplasia (BPH).

Efficacy: What the Trial Data Actually Shows

Finasteride's hair-loss evidence base starts with Kaufman et al. (1998), a key 5-year study published in the Journal of the American Academy of Dermatology. Men with AGA who took finasteride 1 mg daily showed a sustained increase in hair count at the vertex scalp, with improvements peaking around year 2 and remaining above baseline through year 5 [1]. The placebo group continued to lose hair. This trial formed the basis of the FDA's approval of finasteride (brand name Propecia) for male-pattern hair loss.

Dutasteride's strongest AGA evidence comes from Eun et al. (2010), a randomized controlled trial that directly compared dutasteride 0.5 mg to finasteride 1 mg in men with AGA. The study, also published in the Journal of the American Academy of Dermatology, found that dutasteride produced superior hair count increases compared to finasteride at 24 weeks [2]. Target area hair counts rose by 12.2 hairs/cm² in the dutasteride group versus 4.7 hairs/cm² in the finasteride group.

A few things matter about this comparison. The Eun et al. study was 24 weeks, not 5 years. Long-term head-to-head data remains sparse. A 2014 meta-analysis pooling available randomized trials confirmed a small but statistically significant advantage for dutasteride over finasteride in total hair count, though the clinical significance of the difference (whether patients or clinicians can see it) is debated [3].

"Both drugs work. The difference in regrowth between dutasteride and finasteride is real in controlled trials but modest in a clinical mirror," noted Dr. Antonella Tosti, a dermatologist at the University of Miami who has published extensively on alopecia pharmacotherapy.

No three-year or five-year randomized head-to-head trial of dutasteride versus finasteride for AGA has been published as of 2026.

Cost Breakdown: Generic vs Brand

The price gap between these two drugs is large. Here is what patients typically pay.

Finasteride 1 mg (generic Propecia): Retail cash price at major U.S. chain pharmacies ranges from $4 to $15 for a 30-day supply. Costco, Walmart, and Mark Cuban's Cost Plus Drugs have listed it below $5 for 30 tablets. GoodRx-reported median cash prices hover around $9 to $12.

Dutasteride 0.5 mg (generic Avodart): Retail cash price runs $30 to $60 for a 30-day supply of generic capsules. Brand-name Avodart, when dispensed, exceeds $300 per month. GoodRx coupons can reduce the generic to roughly $15 to $25 at select pharmacies, but availability fluctuates because not all locations stock dutasteride routinely.

The reason for the price difference is straightforward. Finasteride went generic in 2006 and has had nearly two decades of multi-manufacturer competition. Dutasteride's U.S. patent expired in 2015, and while generic versions exist, the market has fewer manufacturers and lower prescription volume for the 0.5 mg capsule (the BPH dose also used off-label for hair loss). Lower volume means less aggressive pricing.

For patients paying out of pocket for AGA treatment (which is the majority, since most insurers classify hair loss drugs as cosmetic), the annual cost difference is substantial: roughly $48 to $180 per year for finasteride versus $360 to $720 per year for generic dutasteride.

Insurance and Formulary Realities

Insurance coverage for 5-ARIs depends entirely on the diagnosis code submitted. This is where the FDA-approval distinction creates a practical wall.

Finasteride 1 mg carries an FDA-approved indication for the treatment of male-pattern hair loss (AGA) under the brand name Propecia [4]. Finasteride 5 mg (Proscar) is approved for BPH. Most commercial insurance plans and Medicare Part D formularies list finasteride 5 mg as a tier-1 generic for BPH but exclude the 1 mg tablet when billed under an AGA diagnosis code. The result: a patient with both BPH and hair loss might get the drug covered, while a 28-year-old with only AGA almost certainly will not.

Dutasteride 0.5 mg (Avodart) is FDA-approved exclusively for BPH [5]. It has no approved indication for hair loss in the United States. When prescribed off-label for AGA, insurers will deny the claim. Even for BPH, prior authorization requirements are common; some plans require a documented trial of finasteride 5 mg or tamsulosin before approving dutasteride.

The practical takeaway is blunt. Neither drug is reliably covered by insurance for hair loss. But finasteride's lower cash price makes the coverage gap far less painful.

Pharmacy Access and Stocking

Every retail pharmacy in the United States stocks finasteride. It is one of the most prescribed medications in the country, with over 20 million prescriptions filled annually across the 1 mg and 5 mg strengths [6]. Walk into any CVS, Walgreens, Rite Aid, Walmart, or independent pharmacy, and it will be on the shelf.

Dutasteride stocking is less consistent. Large chain pharmacies carry it, but some independent pharmacies and smaller outlets may need to order it, adding 1 to 3 business days. The capsule formulation also requires specific storage conditions (it is a soft gelatin capsule sensitive to heat), which occasionally causes supply hiccups during summer months.

Telehealth platforms have widened access to both drugs. Companies like Hims, Keeps, and Ro prescribe finasteride as a standard offering. Dutasteride is available through some telehealth platforms but not all, because prescribers vary in their comfort level with off-label use and because some state pharmacy boards have flagged high-volume off-label dutasteride prescribing for review.

Mail-order pharmacies tend to offer better pricing on dutasteride than brick-and-mortar locations. Patients willing to use 90-day mail-order fills can sometimes get generic dutasteride for $20 to $30 per month.

The Off-Label Question

Dutasteride's off-label status in the United States for AGA is not a minor footnote. It shapes prescribing patterns, insurance claims, liability exposure, and patient access.

Off-label prescribing is legal and common. Physicians routinely prescribe drugs for indications beyond their FDA-approved labeling when clinical evidence supports the use. The American Academy of Dermatology's guidelines on AGA acknowledge dutasteride as a treatment option, citing the Eun et al. data and other studies [7]. Off-label does not mean unsupported.

But off-label does mean unprotected in certain ways. If a patient experiences a side effect, the prescriber carries a slightly different liability profile than when prescribing an FDA-approved indication. Insurance denials are automatic. And in some institutional settings (the VA system, certain HMOs), formulary committees restrict off-label dispensing of dutasteride for non-BPH diagnoses.

Japan approved dutasteride for AGA in 2015. South Korea approved it in 2009. These regulatory decisions were based on the same clinical trial data available to the FDA, which chose not to pursue an AGA indication likely because GlaxoSmithKline (Avodart's manufacturer) did not submit a supplemental application for hair loss before patent expiration.

Side Effect Profiles and How They Affect the Cost Calculation

Both drugs share a similar side effect profile because they work through the same pathway. The most commonly reported adverse effects include decreased libido (1.8% with finasteride vs. 3.3% with dutasteride in pooled trial data), erectile dysfunction, and reduced ejaculate volume [1][2].

Dutasteride's longer half-life (approximately 5 weeks vs. 6 to 8 hours for finasteride) means that if a patient experiences side effects, those effects may take longer to resolve after discontinuation. This pharmacokinetic difference is clinically relevant when counseling patients. A trial of finasteride is reversible within days. A trial of dutasteride commits the patient to weeks of drug exposure even after stopping.

From a cost perspective, this asymmetry argues for starting with finasteride. If the cheaper, faster-clearing drug works adequately, there is no clinical or financial reason to escalate. The Endocrine Society's clinical practice guidelines on androgen therapy note that 5-ARI selection should account for patient preference, cost, and reversibility [8].

"I start every AGA patient on finasteride. If after 12 months the response is suboptimal and the patient wants more aggressive DHT suppression, we discuss dutasteride as a second-line option," stated Dr. Jerry Shapiro, a clinical professor of dermatology at NYU Langone, in a published interview on AGA management [9].

Compounding Pharmacies and Alternative Access

Some patients obtain dutasteride through compounding pharmacies, which can formulate custom preparations (including topical dutasteride) at variable pricing. Compounded topical dutasteride has been studied in small trials and is theorized to deliver local DHT suppression with lower systemic absorption [10].

Compounded formulations are not FDA-regulated in the same way as commercially manufactured drugs. Quality varies between pharmacies. The FDA's guidance on compounding permits compounding under specific conditions but does not verify potency or bioequivalence for individual preparations [11].

Pricing for compounded dutasteride solutions ranges from $40 to $120 per month depending on the pharmacy, concentration, and volume. Some telehealth companies offer compounded topical dutasteride/minoxidil combinations at a premium.

For patients who want dutasteride specifically but face access barriers (cost, prescriber reluctance, pharmacy stocking), compounding represents an alternative pathway. It is not a cheaper one.

International Price Comparisons

Outside the United States, the cost comparison shifts. In the United Kingdom, both finasteride and dutasteride are available as generics through the National Health Service, though NHS prescriptions for AGA are uncommon because hair loss is generally classified as cosmetic [12]. Private prescription costs in the UK run approximately £8 to £15 per month for either drug.

In India, generic dutasteride 0.5 mg sells for the equivalent of $1 to $3 per month. Generic finasteride 1 mg sells for under $1 per month. The price ratio is similar (dutasteride costs roughly 2 to 3 times more than finasteride), but the absolute numbers are dramatically lower.

Patients who purchase medications from international online pharmacies should be aware that the FDA does not regulate foreign drug imports for personal use in most cases, and quality assurance varies widely [11].

Who Should Choose Which Drug

The decision tree is simpler than the pharmacology suggests.

Start with finasteride if: the patient is beginning 5-ARI therapy for the first time, cost is a consideration (it almost always is), and the patient wants an FDA-approved option with a well-characterized safety profile and rapid reversibility.

Consider dutasteride if: the patient has used finasteride for 12 or more months with an inadequate response, is willing to pay the higher out-of-pocket cost, understands the off-label status and longer washout period, and has a prescriber comfortable with off-label 5-ARI use for AGA.

Avoid switching prematurely. Finasteride requires a minimum of 6 to 12 months to demonstrate clinical benefit in AGA. Hair cycle biology does not accelerate because a patient is anxious. Switching to dutasteride at month 3 wastes the finasteride trial and resets the clinical clock.

According to the American Hair Loss Association, over 80% of men with AGA who take finasteride 1 mg daily for 2 years will maintain or increase hair count relative to baseline [7]. The number needed to treat for visible improvement is low. Most patients do not need dutasteride.

Combination Therapy Considerations

Some clinicians prescribe a 5-ARI alongside topical minoxidil (Rogaine) for additive benefit. The combination of finasteride plus minoxidil has been studied more extensively than dutasteride plus minoxidil. A 2015 randomized trial published in Dermatologic Therapy found that the combination of finasteride 1 mg plus topical minoxidil 5% produced greater hair density improvements than either agent alone at 12 months [13].

Adding minoxidil to finasteride typically costs an additional $10 to $30 per month for over-the-counter topical solution or foam. Adding it to dutasteride raises the total monthly spend to $45 to $90 or more. For patients already stretching their budget, the finasteride-plus-minoxidil combination offers the better cost-effectiveness ratio compared to dutasteride monotherapy.

Oral minoxidil at low doses (0.625 mg to 2.5 mg daily) is also gaining traction as an off-label AGA treatment and can be combined with either 5-ARI, though cardiovascular monitoring is recommended per the FDA's black box warning on oral minoxidil [14].

The Bottom Line on Cost vs Efficacy

Dutasteride produces marginally better hair counts than finasteride in short-term controlled trials. It costs 3 to 10 times more depending on the source. It lacks an FDA indication for hair loss. It clears the body slowly. It is harder to get covered, harder to find at every pharmacy, and harder to reverse if problems arise.

Finasteride remains the first-line 5-ARI for AGA by every major guideline, every cost-effectiveness analysis, and every practical access metric. Patients who fail finasteride have a reasonable basis to try dutasteride. Patients starting treatment have no evidence-based reason to begin with the more expensive, off-label option.

The annual savings of choosing finasteride over generic dutasteride range from $200 to $550 per year. Over a decade of treatment (typical for AGA management starting in the late 20s or 30s), that difference compounds to $2,000 to $5 to 500 in out-of-pocket spending, with no proven long-term superiority for the costlier drug.